Author

Filip Baert

Connecting the dots: Integrating mechanism of action into advanced treatment decisions in UC (Arena Pharmaceuticals)
Connecting the dots: Integrating mechanism of action into advanced treatment decisions in UC (Arena Pharmaceuticals)

Filip Baert  et al.

Tandem Talk - Drug therapy: The easy and the challenging patient
Tandem Talk - Drug therapy: The easy and the challenging patient

Filip Baert  et al.

COMPREHENSIVE CHARACTERIZATION OF THE EXPOSURE-RESPONSE RELATIONSHIP OF VEDOLIZUMAB IN ULCERATIVE COLITIS: RESULTS FROM THE LOVE-UC STUDY
COMPREHENSIVE CHARACTERIZATION OF THE EXPOSURE-RESPONSE RELATIONSHIP OF VEDOLIZUMAB IN ULCERATIVE COLITIS: RESULTS FROM THE LOVE-UC STUDY

Filip Baert  et al.

HIGHER ENDOSCOPIC AND CLINICAL REMISSION RATES WITH VEDOLIZUMAB IN EARLY THAN IN LATE CROHN’S DISEASE: RESULTS FROM THE LOVE-CD STUDY (LOW COUNTRIES VEDOLIZUMAB IN CD STUDY)
HIGHER ENDOSCOPIC AND CLINICAL REMISSION RATES WITH VEDOLIZUMAB IN EARLY THAN IN LATE CROHN’S DISEASE: RESULTS FROM THE LOVE-CD STUDY (LOW COUNTRIES VEDOLIZUMAB IN CD STUDY)

Filip Baert  et al.

MANOMETRIC DIAGNOSIS AND TREATMENT OF RETROGRADE CRICOPHARYNGEUS DYSFUNCTION (R-CPD)
MANOMETRIC DIAGNOSIS AND TREATMENT OF RETROGRADE CRICOPHARYNGEUS DYSFUNCTION (R-CPD)

Filip Baert  et al.

ETRASIMOD 2MG ONCE DAILY AS TREATMENT FOR MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS
ETRASIMOD 2MG ONCE DAILY AS TREATMENT FOR MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS

Filip Baert  et al.

SWITCHING INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB WAS SAFE AND SUCCESSFUL SHORT TERM IN ULCERATIVE COLITIS AND CROHN PATIENTS – A BELGIAN SINGLE CENTER EXPERIENCE
SWITCHING INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB WAS SAFE AND SUCCESSFUL SHORT TERM IN ULCERATIVE COLITIS AND CROHN PATIENTS – A BELGIAN SINGLE CENTER EXPERIENCE

Filip Baert  et al.

CLINICALLY ADJUSTED VERSUS THERAPEUTIC DRUG MONITORING DOSING REGIMENS WITH ADALIMUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: RESULTS FROM THE SERENE-CD MAINTENANCE STUDY
CLINICALLY ADJUSTED VERSUS THERAPEUTIC DRUG MONITORING DOSING REGIMENS WITH ADALIMUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: RESULTS FROM THE SERENE-CD MAINTENANCE STUDY

Filip Baert  et al.

VEDOLIZUMAB IS ASSOCIATED WITH STEROID-FREE CLINICAL REMISSION AND DISCONTINUATION-FREE SURVIVAL IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE PROCTITIS
VEDOLIZUMAB IS ASSOCIATED WITH STEROID-FREE CLINICAL REMISSION AND DISCONTINUATION-FREE SURVIVAL IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE PROCTITIS

Filip Baert  et al.

IMPACT OF PRIOR BIOLOGIC/JANUS KINASE INHIBITOR THERAPY ON THE EFFICACY OF ETRASIMOD: SUBGROUP ANALYSIS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS
IMPACT OF PRIOR BIOLOGIC/JANUS KINASE INHIBITOR THERAPY ON THE EFFICACY OF ETRASIMOD: SUBGROUP ANALYSIS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS

Filip Baert  et al.

ETRASIMOD 2MG ONCE DAILY AS TREATMENT FOR BIOLOGIC/JANUS KINASE INHIBITOR-NAÏVE AND -EXPERIENCED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: SUBGROUP ANALYSIS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS
ETRASIMOD 2MG ONCE DAILY AS TREATMENT FOR BIOLOGIC/JANUS KINASE INHIBITOR-NAÏVE AND -EXPERIENCED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: SUBGROUP ANALYSIS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS

Filip Baert  et al.

PROPHYLACTIC VERSUS ENDOSCOPY-DRIVEN TREATMENT OF CROHN’S POSTOPERATIVE RECURRENCE: COMPLETED RESULTS OF A RETROSPECTIVE, MULTICENTRIC EUROPEAN STUDY (PORCSE STUDY)
PROPHYLACTIC VERSUS ENDOSCOPY-DRIVEN TREATMENT OF CROHN’S POSTOPERATIVE RECURRENCE: COMPLETED RESULTS OF A RETROSPECTIVE, MULTICENTRIC EUROPEAN STUDY (PORCSE STUDY)

Filip Baert  et al.

Item 1 - 12 / 12
1